Literature DB >> 29904848

OnabotulinumtoxinA in chronic migraine: long-term efficacy in a prophylactic medication free cohort.

Francesca Schiano di Cola1,2, Elisa Pari3, Salvatore Caratozzolo4, Chiara Mancinelli4, Paolo Liberini4, Renata Rao4, Alessandro Padovani4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29904848     DOI： 10.1007/s10072-018-3391-5

Source DB:  PubMed          Journal:  Neurol Sci        ISSN： 1590-1874            Impact factor:   3.307


× No keyword cloud information.
  3 in total

1.  The International Classification of Headache Disorders, 3rd edition (beta version).

Authors: 
Journal:  Cephalalgia       Date:  2013-07       Impact factor: 6.292

2.  OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.

Authors:  David W Dodick; Catherine C Turkel; Ronald E DeGryse; Sheena K Aurora; Stephen D Silberstein; Richard B Lipton; Hans-Christoph Diener; Mitchell F Brin
Journal:  Headache       Date:  2010-05-07       Impact factor: 5.887

3.  Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study.

Authors:  Andrew M Blumenfeld; Richard J Stark; Marshall C Freeman; Amelia Orejudos; Aubrey Manack Adams
Journal:  J Headache Pain       Date:  2018-02-05       Impact factor: 7.277
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.